Business Wire

Booking.com and Antom Partner to Expand Local Payment Options Across Asia

15.1.2025 04:47:00 CET | Business Wire | Press release

Share

Strategic partnership to streamline payment solutions and elevate traveller experience, introducing over 40 new payment methods across 8 key Asian markets

Booking.com, one of the world’s leading travel companies, and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership which will enhance the payment experience for Booking.com customers by integrating diverse payment options across key markets in Asia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114445080/en/

This partnership will enable Booking.com to deliver a more tailored customer experience while unlocking business opportunities across China’s Hong Kong SAR, Indonesia, Japan, Malaysia, Singapore, South Korea, Thailand, and the Philippines — markets with a combined population of approximately 680 million. Each market presents distinct challenges, including varying payment methods, currencies and regulatory frameworks. Antom helps global merchants like Booking.com navigate this complexity by leveraging its extensive payment channel partnerships and deep knowledge of local payment landscapes.

Antom has established local acquiring capabilities in over 40 countries and regions, enabling businesses to integrate hundreds of payment methods and supports transactions in over 100 currencies. It offers businesses seamless access to a diverse range of global payment options, including credit cards, e-wallets, and local payment solutions. By leveraging AI technology, Antom helps merchants enhance transaction security, optimise foreign exchange risk management, reduce costs, and improve operational efficiency through real-time payments and blockchain solutions. Additionally, Antom provides digitisation and digital marketing solutions to support merchants’ business growth.

Booking.com is committed to making it easier to experience the world, with a smooth and seamless payment process being a key factor in enabling travellers to book with ease and confidence. Through its partnership with Antom, the digital travel platform will make over 40 payment options available over time, including online banking, bank transfers, digital wallets and local card payments. Key mobile wallets such as AlipayHK (Hong Kong SAR, China), Boost (Malaysia), GCash (the Philippines), GrabPay (Singapore), Kakao Pay (South Korea), Naver Pay (South Korea), Touch 'n Go eWallet (Malaysia) and TrueMoney (Thailand) will be the first to be introduced as new payment methods. This added flexibility empowers a wider range of customers to use their preferred payment methods, streamlining the checkout process and ensuring quicker, more seamless transactions - ultimately unlocking travel opportunities for more consumers across Asia Pacific.

By integrating Antom’s multi-currency offerings and cross-border settlement capabilities, Booking.com is empowering its global accommodation providers to expand user reach, and optimise payment acceptance and reconciliation across diverse markets. This collaboration will especially benefit smaller properties and holiday rentals that may lack access to traditional payment infrastructures, enabling them to compete more effectively in the global marketplace.

Daniel Marovitz, Senior Vice President of Fintech, at Booking.com commented, "Partnering with Antom allows us to streamline and enhance the payment experience for our travellers across Asia Pacific, integrating a wider range of local payment options that align with regional preferences. This collaboration reflects our commitment to delivering a seamless travel experience from booking to checkout. We look forward to working with Antom to support local businesses and continue advancing a more connected, innovative payment ecosystem for travel."

“We’re excited to partner with Booking.com to expand payment options, broaden customer reach across diverse markets, and support the platform in better serving the unique needs of each region,” said Gary Liu, General Manager of Antom, Ant International. “This partnership reflects our commitment to making payments more efficient and enabling merchants to unlock new growth opportunities in today’s dynamic landscape.”

About Booking.com
Part of Booking Holdings Inc. (NASDAQ: BKNG), Booking.com’s mission is to make it easier for everyone to experience the world. By investing in the technology that helps take the friction out of travel, Booking.com’s marketplace seamlessly connects millions of travellers with memorable experiences every day. For more information, follow @bookingcom on social media or visit globalnews.booking.com.

About Antom
Ant International’s Antom is the leading payment and digitisation services provider for merchants around the world. It offers one-stop, vertical-specific digital payment solutions to meet the payment needs of merchants of all sizes. Antom has established local acquiring capabilities in over 40 markets, with the flexibility to accept payments in more than 100 currencies. It also provides digital marketing solutions and merchant digitisation services to help merchant in digital operations and to better engage with their customers. To learn more, please visit https://www.antom.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114445080/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye